Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilson H Miller

Showing results (41-50 of 168) with videos related to

Pageof 17
Sort By:
Gynecologic Oncology|June 13, 2009
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II studyPatti Power, Gavin Stuart, Amit Oza, et al.
Antiviral Research|June 13, 2008
Retinoids inhibit measles virus in vitro via nuclear retinoid receptor signaling pathwaysClaire Trottier, Sophie Chabot, Koren K Mann, et al.
The Journal of Biological Chemistry|June 12, 2008
Rexinoids modulate steroid and xenobiotic receptor activity by increasing its protein turnover in a calpain-dependent mannerFilippa Pettersson, Nessrine Hanna, Marina Lagodich, et al.
Molecular Cancer Therapeutics|March 29, 2013
Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitor-induced DNA damage and apoptosisLuca A Petruccelli, Filippa Pettersson, Sonia V Del Rincón, et al.
Nucleic Acids Research|November 28, 2007
Retinoic acid modulates chromatin to potentiate tumor necrosis factor alpha signaling on the DIF2 promoterMichael Witcher, Filippa Pettersson, Daphne Dupéré-Richer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2007
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancerPaul Goss, Igor N Bondarenko, Georgiy N Manikhas, et al.
Metabolism: Clinical and Experimental|January 22, 2009
Oxalic acid excretion after intravenous ascorbic acid administrationLine Robitaille, Orval A Mamer, Wilson H Miller, et al.
Melanoma Research|May 14, 2009
Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanomaTim Eisen, José Thomas, Wilson H Miller, et al.
Journal for Immunotherapy of Cancer|March 27, 2021
Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case reportKhashayar Esfahani, Meagan-Helen Henderson Berg, Hanieh Zargham, et al.
Journal of Clinical Pharmacology|March 6, 2003
The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal functionAndrej Skerjanec, James Berenson, ChyiHung Hsu, et al.
Pageof 17

Showing results (41-50 of 168) with videos related to

Sort By:
Pageof 17
Gynecologic Oncology|June 13, 2009
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II studyPatti Power, Gavin Stuart, Amit Oza, et al.
Antiviral Research|June 13, 2008
Retinoids inhibit measles virus in vitro via nuclear retinoid receptor signaling pathwaysClaire Trottier, Sophie Chabot, Koren K Mann, et al.
The Journal of Biological Chemistry|June 12, 2008
Rexinoids modulate steroid and xenobiotic receptor activity by increasing its protein turnover in a calpain-dependent mannerFilippa Pettersson, Nessrine Hanna, Marina Lagodich, et al.
Molecular Cancer Therapeutics|March 29, 2013
Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitor-induced DNA damage and apoptosisLuca A Petruccelli, Filippa Pettersson, Sonia V Del Rincón, et al.
Nucleic Acids Research|November 28, 2007
Retinoic acid modulates chromatin to potentiate tumor necrosis factor alpha signaling on the DIF2 promoterMichael Witcher, Filippa Pettersson, Daphne Dupéré-Richer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2007
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancerPaul Goss, Igor N Bondarenko, Georgiy N Manikhas, et al.
Metabolism: Clinical and Experimental|January 22, 2009
Oxalic acid excretion after intravenous ascorbic acid administrationLine Robitaille, Orval A Mamer, Wilson H Miller, et al.
Melanoma Research|May 14, 2009
Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanomaTim Eisen, José Thomas, Wilson H Miller, et al.
Journal for Immunotherapy of Cancer|March 27, 2021
Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case reportKhashayar Esfahani, Meagan-Helen Henderson Berg, Hanieh Zargham, et al.
Journal of Clinical Pharmacology|March 6, 2003
The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal functionAndrej Skerjanec, James Berenson, ChyiHung Hsu, et al.
Pageof 17